If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Our group explores various epigenetic processes to identify precise signaling events that takes place in the cancer cells either during oncogenesis or upon exposure to various chemotherapeutic agents, including immune therapies (Mahajan et al., Nature Structural & Molecular Biology, 2012). To effectively overcome cancer cell proliferation, we have developed next generation of small molecule inhibitors (Mahajan et al., Cancer Cell, 2017), which are currently being evaluated in pre-IND studies with the goal of clinical trials in near future. Our inhibitors targeting ACK1 and WEE1 kinases have been highly promising in overcoming drug-resistant prostate and breast cancers. We have also developed a new class of immune modulators. For further information, visit our lab website: https://sites.wustl.edu/mahajann/

Fingerprint Dive into the research topics where Nupam Mahajan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1934 Citations
  • 29 Article
  • 4 Review article
  • 1 Comment/debate
  • 1 Short survey

The DNA methylation landscape of advanced prostate cancer

Zhao, S. G., Chen, W. S., Li, H., Foye, A., Zhang, M., Sjöström, M., Aggarwal, R., Playdle, D., Liao, A., Alumkal, J. J., Das, R., Chou, J., Hua, J. T., Barnard, T. J., Bailey, A. M., Chow, E. D., Perry, M. D., Dang, H. X., Yang, R., Moussavi-Baygi, R. & 49 others, Zhang, L., Alshalalfa, M., Laura Chang, S., Houlahan, K. E., Shiah, Y. J., Beer, T. M., Thomas, G., Chi, K. N., Gleave, M., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Yvonne Kim, M., Fong, L., Spratt, D. E., Morgan, T. M., Bose, R., Huang, F. W., Li, H., Chesner, L., Shenoy, T., Goodarzi, H., Asangani, I. A., Sandhu, S., Lang, J. M., Mahajan, N. P., Lara, P. N., Evans, C. P., Febbo, P., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Zwart, W., Costello, J. F., Luo, J., Tomlins, S. A., Wyatt, A. W., Dehm, S. M., Ashworth, A., Gilbert, L. A., Boutros, P. C., Farh, K., Chinnaiyan, A. M., Maher, C. A., Small, E. J., Quigley, D. A. & Feng, F. Y., Aug 1 2020, In : Nature Genetics. 52, 8, p. 778-789 12 p.

Research output: Contribution to journalArticle

  • 2 Scopus citations

    Blockade of ACK1/TNK2 to Squelch the Survival of Prostate Cancer Stem-like Cells

    Mahajan, N. P., Coppola, D., Kim, J., Lawrence, H. R., Lawrence, N. J. & Mahajan, K., Dec 1 2018, In : Scientific reports. 8, 1, 1954.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations

    Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer

    Bossan, A., Ottman, R., Andl, T., Hasan, M. F., Mahajan, N., Coppola, D. & Chakrabarti, R., Dec 17 2018, In : BMC Cancer. 18, 1, 1257.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations

    ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer

    Mahajan, K., Malla, P., Lawrence, H. R., Chen, Z., Kumar-Sinha, C., Malik, R., Shukla, S., Kim, J., Coppola, D., Lawrence, N. J. & Mahajan, N. P., Jun 12 2017, In : Cancer Cell. 31, 6, p. 790-803.e8

    Research output: Contribution to journalArticle

    Open Access
  • 27 Scopus citations

    The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

    Wu, X., Zahari, M. S., Renuse, S., Kelkar, D. S., Bharbuiya, M. A., Rojas, P. L., Stearns, V., Gabrielson, E., Malla, P., Sukumar, S., Mahajan, N. P. & Pandey, A., Jan 1 2017, In : Oncotarget. 8, 2, p. 2971-2983 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 8 Scopus citations